EdiGene (2)

Executive Summary

EdiGene is a clinical-stage biotechnology company based in China, focused on developing gene-editing therapies using CRISPR technology. The company's lead program targets beta-thalassemia and sickle cell disease, with a pipeline that includes ex vivo editing of hematopoietic stem cells. Despite limited public data, EdiGene has advanced its lead candidate, ET-01, into clinical trials in China and plans to expand into other genetic disorders. The company operates in the competitive gene editing space, but its focus on prevalent Asian genetic diseases provides a niche market opportunity. With ongoing trials and potential regulatory milestones, EdiGene represents a speculative investment in the gene therapy landscape.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 clinical data readout for ET-01 in beta-thalassemia40% success
• Q2 2027Regulatory update for sickle cell disease program30% success